Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a renowned national high-tech enterprise that has undergone significant changes since its establishment. Originally founded as the Zhangzhou Pharmaceutical Factory in 1956, the company was restructured into Pien Tze Huang Pharmaceutical in December 1999.

Tags

Digestive System Disorders

Other Diseases

Skin and Musculoskeletal Diseases

Herbal medicine

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Nervous System Diseases	2
Infectious Diseases	2

Top 5 Drug Type	Count

Herbal medicine	4
Small molecule drug	3
Chemical drugs	1

Top 5 Target	Count

FGFR2 x FGFR3	1

Drugs associated with Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

FuFangPianZihuangRuanGao

Target-

Mechanism-

Active Org.

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Originator Org.

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Active Indication

Acne Vulgaris [+4]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1999

PianZiHuang

Target-

Mechanism-

Active Org.

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Originator Org.

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Active Indication

Furunculosis [+3]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1999

FuFangPianZihuangZhiChuangRuanGao

Target-

Mechanism-

Active Org.

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Originator Org.

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Active Indication

Hemorrhoids

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1996

Clinical Trials associated with Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

CTR20223188 / CompletedPhase 1

评价在中国健康受试者体内给予PZH2108片的单中心、随机、双盲、安慰剂对照、单次递增给药、多次给药及食物影响的安全性、耐受性及药代动力学特性的I期临床研究

[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic properties of PZH2108 tablets in healthy Chinese subjects, with single-center, randomized, double-blind, placebo-controlled, single-ascending dosing, multiple dosing and food effects

1）评估健康成人单次口服、多次口服PZH2108片的安全性和耐受性； 2）评估健康成人单次/多次口服PZH2108片的药代动力学（PK）特征及进食对健康成人单次口服PZH2108片PK的影响； 3）探索研究口服PZH2108片对于冷刺激疼痛（PD）的影响。

[Translation]

1) Evaluate the safety and tolerability of single and multiple oral administration of PZH2108 tablets in healthy adults; 2) Evaluate the pharmacokinetic (PK) characteristics of single/multiple oral administration of PZH2108 tablets in healthy adults and the effect of food on the PK of single oral administration of PZH2108 tablets in healthy adults; 3) Explore the effect of oral administration of PZH2108 tablets on cold pain (PD).

Start Date27 Dec 2022

Sponsor / Collaborator

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

CTR20213258 / Active, not recruitingPhase 2

片仔癀二线治疗不可切除原发性肝癌（瘀毒蕴结证）有效性与安全性的多中心、随机、双盲双模拟、阳性药平行对照II期临床试验

[Translation] A multicenter, randomized, double-blind, double-dummy, positive drug parallel controlled phase II clinical trial on the efficacy and safety of Pien Tze Huang as a second-line treatment for unresectable primary liver cancer (stasis and toxicity syndrome)

1.评价针对至少接受一次一线系统治疗失败或不可耐受的不可切除原发性肝癌患者，初步比较片仔癀与安替可胶囊二线治疗不可切除原发性肝癌的有效性；2.观察片仔癀用于治疗不可切除原发性肝癌受试者的安全性。

[Translation]

1. To evaluate the effectiveness of Pien Tze Huang and Antico Capsules as second-line treatments for patients with unresectable primary liver cancer who have failed or cannot tolerate at least one first-line systemic treatment; 2. To observe the safety of Pien Tze Huang in the treatment of subjects with unresectable primary liver cancer.

Start Date25 Jan 2022

Sponsor / Collaborator

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

CTR20210967 / RecruitingPhase 1/2

评价 PZH2111 片治疗 FGFR 基因异常晚期实体瘤患者及 FGFR2 基因融合突变晚期肝内胆管细胞癌患者的安全性、有效性及药代动力学特征的开放、多中心、I/II 期临床研究

[Translation] An open, multicenter, phase I/II clinical study to evaluate the safety, efficacy, and pharmacokinetic characteristics of PZH2111 tablets in the treatment of patients with advanced solid tumors with FGFR gene abnormalities and patients with advanced intrahepatic cholangiocarcinoma with FGFR2 gene fusion mutations

1）评价 PZH2111 片在晚期实体瘤患者中的安全性和耐受性，并确定 PZH2111 片的最大耐受剂量(MTD)或最大爬坡剂量(MAD)，以及后续推荐剂量(RD)。2）评价 PZH2111 片在晚期胆管细胞癌患者中的抗肿瘤活性。

[Translation]

1) To evaluate the safety and tolerability of PZH2111 tablets in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD) or maximum escalation dose (MAD) of PZH2111 tablets, as well as the subsequent recommended dose (RD). 2) To evaluate the anti-tumor activity of PZH2111 tablets in patients with advanced cholangiocarcinoma.

Start Date27 Dec 2021

Sponsor / Collaborator

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

0 Patents (Medical) associated with Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Literatures (Medical) associated with Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

02 Aug 2024·Horticulture Research

Panax notoginseng: panoramagram of phytochemical and pharmacological properties, biosynthesis, and regulation and production of ginsenosides

Review

Author: Chen, Shilin ; Shi, Liping ; Zhang, Zhaoyu ; Wei, Guangfei ; Zhang, Guozhuang ; Zheng, Yuqing ; Huang, Ziying ; Zheng, Wenke ; Wang, Bo ; Li, Mengzhi ; Dong, Linlin ; Wei, Tengyun ; Zhang, Xiao

AbstractPanax notoginseng is a famous perennial herb widely used as material for medicine and health-care food. Due to its various therapeutic effects, research work on P. notoginseng has rapidly increased in recent years, urging a comprehensive review of research progress on this important medicinal plant. Here, we summarize the latest studies on the representative bioactive constituents of P. notoginseng and their multiple pharmacological effects, like cardiovascular protection, anti-tumor, and immunomodulatory activities. More importantly, we emphasize the biosynthesis and regulation of ginsenosides, which are the main bioactive ingredients of P. notoginseng. Key enzymes and transcription factors (TFs) involved in the biosynthesis of ginsenosides are reviewed, including diverse CYP450s, UGTs, bHLH, and ERF TFs. We also construct a transcriptional regulatory network based on multi-omics data and predicted candidate TFs mediating the biosynthesis of ginsenosides. Finally, the current three major biotechnological approaches for ginsenoside production are highlighted. This review covers advances in the past decades, providing insights into quality evaluation and perspectives for the rational utilization and development of P. notoginseng resources. Modern omics technologies facilitate the exploration of the molecular mechanisms of ginsenoside biosynthesis, which is crucial to the breeding of novel P. notoginseng varieties. The identification of functional enzymes for biosynthesizing ginsenosides will lead to the formulation of potential strategies for the efficient and large-scale production of specific ginsenosides.

01 Mar 2024·Biomedicine & Pharmacotherapy

Xinshubao tablet rescues cognitive dysfunction in a mouse model of vascular dementia: Involvement of neurogenesis and neuroinflammation

Article

Author: Li, Xian-Yu ; Hou, Jin-Li ; Wang, Shi-Cong ; Li, Sen ; Guo, Fei-Fei ; Zhang, Feng-Rong ; Yu, Juan ; Xiao, Hong-He ; Yang, Hong-Jun

Vascular dementia (VaD) represents a severe cognitive dysfunction syndrome closed linked to cardiovascular function. In the present study, we assessed the potential of Xinshubao tablet (XSB), a traditional Chinese prescription widely used for cardiovascular diseases, to mitigate neuropathological damage in a mouse model of VaD and elucidated the underlying mechanisms. Our findings revealed that oral administration of XSB rescued the cardiac dysfunction resulting from bilateral common carotid artery stenosis (BCAS), improved the cerebral blood flow (CBF) and cognitive function, reduced white matter injury, inhibited excessive microglial and astrocytic activation, stimulated hippocampal neurogenesis, and reduced neural apoptosis in the brains of BCAS mice. Mechanistically, RNA-seq analysis indicated that XSB treatment was significantly associated with neuroinflammation, vasculature development, and synaptic transmission, which were further confirmed by q-PCR assays. Western blot results revealed that XSB treatment hindered the nuclear translocation of nuclear factor-κB (NF-κB), thereby suppressing the NF-κB signaling pathway. These results collectively demonstrated that XSB could ameliorate cognitive dysfunction caused by BCAS through regulating CBF, reducing white matter lesions, suppressing glial activation, promoting neurogenesis, and mitigating neuroinflammation. Notably, the NF-κB signaling pathway emerged as a pivotal player in this mechanism.

01 Feb 2024·Chinese Journal of Integrative Medicine

Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity

Article

Author: Luo, Zhi-Yi ; Zheng, Xiao-Yuan ; Liu, Cong-Sheng ; Zhao, Bi-Xing ; Zhang, Xiang-Zhi ; Liu, Wen-Han ; Yang, Ye ; Tian, Qi ; Li, Qin ; Liu, Xiao-Long ; Zhuang, Qiu-Yu ; Chen, Wei ; Wang, Ying-Chao ; Chen, Ming-Sheng ; Cheng, Niang-Mei

OBJECTIVETo investigate the effects of Pien Tze Huang (PZH) on the migration and invasion of HCC cells and underlying molecular mechanism.METHODSCell counting kit-8 (CCK-8) was applied to evaluate the cell viabilities of SMMC-7721, SK-Hep-1, C3A and HL-7702 (6 × 10³ cells/well) co-incubated with different concentrations of PZH (0, 0.2, 0.4, 0.6, 0.8 mg/mL) for 24 h. Transwell, wound healing assay, CCK-8 and Annexin V-FITC/PI staining were conducted to investigate the effects of PZH on the migration, invasion, proliferation and apoptosis of SK-Hep-1 and SMMC-7721 cells (650 µ g/mL for SK-Hep-1 cells and 330 µ g/mL for SMMC-7721 cells), respectively. In vivo, lung metastasis mouse model constructed by tail vein injection of HCC cells was used for evaluating the anti-metastasis function of PZH. SK-Hep-1 cells (10⁶ cells/200 µ L per mice) were injected into B-NDG mice via tail vein. Totally 8 mice were randomly divided into PZH and control groups, 4 mice in each group. After 2-d inoculation, mice in the PZH group were administered with PZH (250 mg/kg, daily) and mice in the control group received only vehicle (PBS) from the 2nd day after xenograft to day 17. Transcriptome analysis based on RNA-seq was subsequently used for deciphering anti-tumor mechanism of PZH. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were applied to verify RNA-seq results. Luciferase reporter assay was performed to examine the transcriptional activity of yes-associated protein (YAP).RESULTSPZH treatment significantly inhibited the migration, invasion, proliferation and promoted the apoptosis of HCC cells in vitro and in vivo (P<0.01). Transcriptome analysis indicated that Hippo signaling pathway was associated with anti-metastasis function of PZH. Mechanical study showed PZH significantly inhibited the expressions of platelet derived growth factor receptor beta (PDGFRB), YAP, connective tissue growth factor (CCN2), N-cadherin, vimentin and matrix metallopeptidase 2 (MMP2, P<0.01). Meanwhile, the phosphorylation of YAP was also enhanced by PZH treatment in vitro and in vivo. Furthermore, PZH played roles in inhibiting the transcriptional activity of YAP.CONCLUSIONPZH restrained migration, invasion and epithelial-mesenchymal transition of HCC cells through repressing PDGFRB/YAP/CCN2 axis.

100 Deals associated with Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

100 Translational Medicine associated with Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

IND Application

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

FuFangPianZihuangRuanGao	Chickenpox More	Approved
FuFangPianZihuangZhiChuangRuanGao	Hemorrhoids More	Approved
PianZiHuang	Wounds and Injuries More	Approved
PZH-2111 ( FGFR2 x FGFR3 )	Advanced Malignant Solid Neoplasm More	Phase 2 Clinical
Maqianzi Zongjian Nangpao Gel	Pain More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis